Published in Hematology Week, December 19th, 2005
SPIRIT II is a 300-patient, randomized clinical trial evaluating XIENCE V, an everolimus-eluting coronary stent system utilizing Guidant's cobalt chromium rapid-exchange MULTI-LINK VISION coronary stent system platform. This single-blind, prospective, randomized, noninferiority study further evaluates the XIENCE V compared to the TAXUS Express 2 paclitaxel-eluting coronary stent system for the treatment of coronary artery disease. Results of the SPIRIT II study will provide additional clinical data to support the launch of XIENCE V in several...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.